美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Leverage Shares 2X Long ENTG Daily ETF

7.15

+0.26283.82%

盤後：6.89-0.2628-3.68%16:10 EDT

成交量：217

成交額：1,527

市值：17.87萬

市盈率：- -

高：7.15

開：6.79

低：7.15

收：6.89

52周最高：14.51

52周最低：4.60

股本：2.50萬

流通股本：2.50萬

量比：0.09

換手率：0.87%

股息：- -

股息率：- -

淨資產收益率：--

總資產收益率：--

市淨率：--

市盈率(LYR):- -

資料載入中...

總覽公司新聞公告

概念

no data

沒有相關數據

資金流向

資金流入：

資金流出：

新聞

更多創新藥有望納入醫保報銷

創新生物製劑落地中國！雙適應症惠及重度哮喘與鼻息肉患者

泰適卓®雙適應症在華上市，為重度哮喘、慢性鼻竇炎伴鼻息肉患者提供生物製劑創新治療選擇

康諾亞-B(02162)：CM512(TSLP x IL-13雙抗)注射液用於慢性鼻竇炎伴鼻息肉患者的II期臨床試驗達到所有研究終點

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎證券香港 | 輕鬆買賣美股港股A股/美債/ETF/Crypto/期權期貨","description":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","keywords":"老虎證券,老虎證券開戶,老虎證券香港,老虎證券投資,老虎證券美股,老虎證券登錄,證券開戶,證券公司開戶,股票開戶,香港證券公司,香港證券,證券公司,美股投資平台,小額投資理財,投資app,投資平台,股票買賣,買賣股票平台,炒股app,證券app,新手投資","social":{"ogDescription":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrcrest.com/hant/stock/ENTL"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"ENTL","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ENTL\",,,,,undefined,":{"symbol":"ENTL","market":"US","secType":"STK","nameCN":"Leverage Shares 2X Long ENTG Daily ETF","latestPrice":7.1498,"timestamp":1789156800000,"preClose":6.887,"halted":0,"volume":217,"hourTrading":{"tag":"盘后","latestPrice":6.887,"preClose":7.1498,"latestTime":"16:10 EDT","volume":6,"amount":42.8988,"timestamp":1789157404480,"change":-0.2628,"changeRate":-0.036756,"amplitude":0},"delay":0,"changeRate":0.03815885000726011,"floatShares":25000,"shares":25000,"eps":0,"marketStatus":"休市中","change":0.2628,"latestTime":"09-11 16:00:00 EDT","open":6.79,"high":7.1498,"low":7.1498,"amount":1527,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"盤前交易","tradingStatus":1,"beginTime":1789372800000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":1422507600000,"exchange":"CBOE","adjPreClose":6.887,"nav":6.88,"aum":172000,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":6.887,"preClose":7.1498,"latestTime":"16:10 EDT","volume":6,"amount":42.8988,"timestamp":1789157404480,"change":-0.2628,"changeRate":-0.036756,"amplitude":0},"volumeRatio":0.09015371644882184},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ENTL\",,,,,undefined,":{"symbol":"ENTL","floatShares":25000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.09015371644882184,"shares":25000,"dividePrice":0,"high":7.1498,"amplitude":0,"preClose":6.887,"low":7.1498,"week52Low":4.6027,"pbRate":"--","week52High":14.5091,"institutionHeld":0,"latestPrice":7.1498,"eps":0,"divideRate":0,"volume":217,"delay":0,"ttmEps":0,"open":6.79,"prevYearClose":12.45,"prevWeekClose":7.04,"prevMonthClose":6.76,"prevQuarterClose":14,"fiveDayClose":6.2888,"twentyDayClose":10.1848},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ENTL\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ENTL\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ENTL\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ENTL\",pageSize:4,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2664383252","title":"更多創新藥有望納入醫保報銷","url":"https://stock-news.laohu8.com/highlight/detail?id=2664383252","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664383252?lang=zh_tw&edition=fundamental","pubTime":"2026-09-04 10:20","pubTimestamp":1788488426,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["HART","06978","159992","BK1574","MEDX","BK4588","BK4585","IBBQ","LNGR","BK1161","IHI","ENTL","PSCH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660484381","title":"創新生物製劑落地中國！雙適應症惠及重度哮喘與鼻息肉患者","url":"https://stock-news.laohu8.com/highlight/detail?id=2660484381","media":"上观新闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660484381?lang=zh_tw&edition=fundamental","pubTime":"2026-08-17 18:40","pubTimestamp":1786963204,"startTime":"0","endTime":"0","summary":"今天，阿斯利康宣布，泰适卓?（英文商品名：Tezspire?，通用名：特泽利尤单抗注射液）在中国正式获批上市。依托两项关键III期临床研究的积极成果，该药物在国内斩获双重适应症，可用于成人及12岁以上青少年重度哮喘的维持治疗，同时能够联合鼻用糖皮质激素，治疗经系统性糖皮质激素、手术治疗后仍无法有效控制病情的慢性鼻窦炎伴鼻息肉成人患者。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608173843332125.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608173843332125.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["TSDD","TSLG","09366","TSLZ","TSLY","TSLT","TSL","TSII","CRSH","ELOL","09766","TSLS","TESL","TSLO","TSLW","TEST","TSLP","TSLI","TSLL","TSLR","07366","TSYY","07766","TSLQ","TLA","ENTL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660334481","title":"泰適卓®雙適應症在華上市，為重度哮喘、慢性鼻竇炎伴鼻息肉患者提供生物製劑創新治療選擇","url":"https://stock-news.laohu8.com/highlight/detail?id=2660334481","media":"美通社","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660334481?lang=zh_tw&edition=fundamental","pubTime":"2026-08-17 16:21","pubTimestamp":1786954860,"startTime":"0","endTime":"0","summary":"特泽利尤单抗的上市，为慢性鼻窦炎伴鼻息肉患者带来了新的治疗选择，有望帮助他们实现长期疾病控制，改善生活质量。携双适应症在华上市，特泽利尤单抗有望充分释放上游炎症通路靶点的临床价值，进一步完善我们在哮喘领域从轻中度到重度的全病程疾病管理布局，加速哮喘治疗迈向'临床治愈'愿景，同时满足广大慢性鼻窦炎伴鼻息肉患者的未尽之需。其中，高达10%的哮喘患者为重度哮喘22,23。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"prnasia","url":"http://wwwold.prnasia.com/story/archive/5027377_ZH27377_1","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://wwwold.prnasia.com/story/archive/5027377_ZH27377_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["BK4007","LU2456880835.USD","LU2237443465.HKD","LU2237443549.SGD","LU2462157665.USD","LU0708994859.HKD","LU0320765992.SGD","LU0432979614.USD","BK4588","BK4585","LU2236285917.USD","LU2089984988.USD","LU0029864427.USD","LU0289739699.SGD","IPOS","LU1829250122.USD","LU0109394709.USD","BK4568","LU0310800379.SGD","LU0889565916.HKD","LU2237443382.USD","AZNH","LU1267930573.SGD","LU2237443895.HKD","AZN","LU0058720904.USD","LU0128525929.USD","IE00B3T34201.USD","LU2237443622.USD","LU2468319806.SGD","LU2237443978.SGD","ENTL","LU2417539215.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658605178","title":"康諾亞-B(02162)：CM512(TSLP x IL-13雙抗)注射液用於慢性鼻竇炎伴鼻息肉患者的II期臨床試驗達到所有研究終點","url":"https://stock-news.laohu8.com/highlight/detail?id=2658605178","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658605178?lang=zh_tw&edition=fundamental","pubTime":"2026-08-10 08:09","pubTimestamp":1786320562,"startTime":"0","endTime":"0","summary":"智通财经APP讯，康诺亚-B 发布公告，公司自主研发的1类新药CM512注射液治疗慢性鼻窦炎伴鼻息肉的II期临床研究已完成数据揭盲及初步统计分析。结果显示：1、CM512达到了全部研究终点，各剂量组疗效表现相当。CM512快速起效，给药第4周即可快速缩小鼻息肉同时显著改善鼻塞，并促进嗅觉功能恢复。基于此II期结果，公司正在快速启动CM512注射液治疗CRSwNP的临床III期研究，并明确300mg，半年给药一次为用药方案。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1477751.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","ENTL","02162","IBBQ","BK1574","BK1583","IBBJ","PSYK","BK1587","BMED","MDTX"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":4,"totalPage":2,"pageCount":1,"totalSize":7,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/ENTL\",params:#limit:6,delay:false,,,undefined,":[]}}